{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:43Z","timestamp":1794047503428,"version":"4.8.0"},"reference-count":54,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>CD47 overexpression has been associated with tumor cell survival. We present the safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of evorpacept, a novel fusion protein comprising a high-affinity CD47\u2013SIRP\u03b1 immune checkpoint inhibitor to promote tumor cell phagocytosis and inactive Fc domain to spare healthy cells, plus rituximab in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (NHL) from the phase I ASPEN-01 study. Thirty-three patients received intravenous evorpacept (10 mg\/kg [N=22] or 15 mg\/kg [N=11] once weekly) until disease progression, in combination with fixed-duration intravenous rituximab (375 mg\/m2 once weekly for 4 weeks, then every 4 weeks for 8 months). Evorpacept plus rituximab was well tolerated, with no dose-limiting toxicities; no maximum tolerated dose was identified. The most common treatment-related adverse events (TRAE) were rash (24.2%) and fatigue (15.2%); most TRAE (70.0%) were mild-to-moderate in severity. Four (12.1%) patients reported grade 3 TRAE: anemia, neutropenia, decreased neutrophil count, increased alanine aminotransferase, decreased lymphocyte count, and decreased platelet count (1 of each). Two (6.1%) patients experienced grade 4 TRAE (neutropenia, decreased neutrophil count). Six (18.2%) patients experienced serious AE (not treatment-related): asthma, dyspnea, respiratory failure, gastrointestinal infection, pneumonia, cardiac failure, and disease progression (1 of each). Two (6.1%) deaths occurred (not treatment-related). Pharmacokinetics\/ pharmacodynamics were consistent with previous studies, with complete CD47 target occupancy (\u226585%) achieved at both doses. In response-evaluable patients (N=32), objective response rate was 50.0% (95% confidence interval: 33.1-69.8%). The safety, tolerability, and promising anti-tumor activity of evorpacept plus rituximab support continued evaluation of this combination in NHL (clinicaltrials gov. Identifier: NCT03013218).<\/jats:p>","DOI":"10.3324\/haematol.2024.286208","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T05:14:52Z","timestamp":1744262092000},"page":"2102-2112","source":"Crossref","is-referenced-by-count":13,"title":["Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study"],"prefix":"10.3324","volume":"110","author":[{"given":"Tae Min","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal J.","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Soumerai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin F.","family":"Gainor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wells","family":"Messersmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Fanning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanhong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Forgie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong I.","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia S.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"78769","doi-asserted-by":"crossref","unstructured":"Willingham SB, Volkmer J-P, Gentles AJ. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012; 109(17):6662-6667.","DOI":"10.1073\/pnas.1121623109"},{"key":"78770","doi-asserted-by":"crossref","unstructured":"Oldenborg P-A. CD47: a cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease. ISRN Hematol. 2013; 2013:614619.","DOI":"10.1155\/2013\/614619"},{"key":"78771","doi-asserted-by":"crossref","unstructured":"Lu Q, Chen X, Wang S, Lu Y, Yang C, Jiang G. Potential new cancer immunotherapy: anti-CD47-SIRP\u03b1 antibodies. Onco Targets Ther. 2020; 13:9323-9331.","DOI":"10.2147\/OTT.S249822"},{"key":"78772","doi-asserted-by":"crossref","unstructured":"Jiang Z, Sun H, Yu J, Tian W, Song Y. Targeting CD47 for cancer immunotherapy. J Hematol Oncol. 2021; 14(1):180.","DOI":"10.1186\/s13045-021-01197-w"},{"key":"78773","doi-asserted-by":"crossref","unstructured":"Yoshida K, Tsujimoto H, Matsumura K. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med. 2015; 4(9):1322-1333.","DOI":"10.1002\/cam4.478"},{"key":"78774","doi-asserted-by":"crossref","unstructured":"Liu J, Wang L, Zhao F. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One. 2015; 10(9):e0137345.","DOI":"10.1371\/journal.pone.0137345"},{"key":"78775","doi-asserted-by":"crossref","unstructured":"Liu X, Pu Y, Cron K. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015; 21(10):1209-1215.","DOI":"10.1038\/nm.3931"},{"key":"78776","doi-asserted-by":"crossref","unstructured":"Advani R, Flinn I, Popplewell L. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma. N Engl J Med. 2018; 379(18):1711-1721.","DOI":"10.1056\/NEJMoa1807315"},{"key":"78777","doi-asserted-by":"crossref","unstructured":"Sockolosky JT, Dougan M, Ingram JR. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci U S A. 2016; 113(19):E2646-E2654.","DOI":"10.1073\/pnas.1604268113"},{"key":"78778","doi-asserted-by":"crossref","unstructured":"Petrova PS, Viller NN, Wong M. TTI-621 (SIRP\u03b1Fc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding. Clin Cancer Res. 2017; 23(4):1068-1079.","DOI":"10.1158\/1078-0432.CCR-16-1700"},{"key":"78779","doi-asserted-by":"crossref","unstructured":"Sikic BI, Lakhani N, Patnaik A. First-in-human, first-inclass phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019; 37(12):946-953.","DOI":"10.1200\/JCO.18.02018"},{"key":"78780","doi-asserted-by":"crossref","unstructured":"Zhang W, Huang Q, Xiao W. Advances in anti-tumor treatments targeting the CD47\/SIRP\u03b1 axis. Front Immunol. 2020; 11:18.","DOI":"10.3389\/fimmu.2020.00018"},{"key":"78781","doi-asserted-by":"crossref","unstructured":"Kauder SE, Kuo TC, Harrabi O. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS One. 2018; 13(8):e0201832.","DOI":"10.1371\/journal.pone.0201832"},{"key":"78782","doi-asserted-by":"crossref","unstructured":"Kim TY, Yoon MS, Hustinx H, Sim J, Wong HI, Hyungsuk K. Assessing and mitigating the interference of ALX148, a novel CD47 blocking agent, in pretransfusion compatibility testing. Transfusion. 2020; 60(10):2399-2407.","DOI":"10.1111\/trf.16009"},{"key":"78783","doi-asserted-by":"crossref","unstructured":"Wan H, Chow L, Gainor J. Pharmacodynamic biomarker characterization of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy. Proc Am Soc Clin Oncol. 2020; 38(Suppl 15)","DOI":"10.1200\/JCO.2019.37.15_suppl.2514"},{"key":"78784","doi-asserted-by":"crossref","unstructured":"Lakhani NJ, Chow LQM, Gainor JF. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and doseexpansion study. Lancet Oncol. 2021; 22(12):1740-1751.","DOI":"10.1016\/S1470-2045(21)00584-2"},{"key":"78785","doi-asserted-by":"crossref","unstructured":"Chao MP, Alizadeh AA, Tang C. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010; 142(5):699-713.","DOI":"10.1016\/j.cell.2010.07.044"},{"key":"78786","unstructured":"Gilead Sciences, Inc. Press Release, February 07, 2024: Gilead statement on discontinuation of phase 3 ENHANCE-3 study in AML. 2024."},{"key":"78787","doi-asserted-by":"crossref","unstructured":"Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997; 89(15):1138-1147.","DOI":"10.1093\/jnci\/89.15.1138"},{"key":"78788","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"78789","doi-asserted-by":"crossref","unstructured":"Del Poeta, Del Principe MI, Buccisano F. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer. 2008; 112(1):119-128.","DOI":"10.1002\/cncr.23144"},{"key":"78790","doi-asserted-by":"crossref","unstructured":"Byrd JC, Peterson BL, Morrison VA. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003; 101(1):6-14.","DOI":"10.1182\/blood-2002-04-1258"},{"key":"78791","unstructured":"National Cancer Institute: Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE). 2024."},{"key":"78792","doi-asserted-by":"crossref","unstructured":"Funt SA, Grivas P, Gao X. Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la\/mUC): phase 1a dose escalation results. J Clin Oncol. 2024; 42(Suppl 16):4575.","DOI":"10.1200\/JCO.2024.42.16_suppl.4575"},{"key":"78793","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Erba H, Sanikommu S. Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with azacitidine: a phase 1\/2 study in patients with myelodysplastic syndrome (ASPEN-02). Blood. 2021; 138(Suppl 1):2601.","DOI":"10.1182\/blood-2021-146547"},{"key":"78794","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Przespolewski A, Abaza Y. Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with azacitidine and venetoclax in patients with acute myeloid leukemia (ASPEN-05): results from phase 1a dose escalation part. Blood. 2022; 140(Suppl 1):9046-9047.","DOI":"10.1182\/blood-2022-157606"},{"key":"78795","doi-asserted-by":"crossref","unstructured":"Ansell SM, Maris MB, Lesokhin AM. Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2021; 27(8):2190-2199.","DOI":"10.1158\/1078-0432.CCR-20-3706"},{"key":"78796","doi-asserted-by":"crossref","unstructured":"Sallman DA, Al Malki MM, Asch AS. Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase 1b study. J Clin Oncol. 2023; 41(15):2815-2826.","DOI":"10.1200\/JCO.22.01794"},{"key":"78797","doi-asserted-by":"crossref","unstructured":"Zeidan AM, DeAngelo DJ, Palmer J. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann Hematol. 2022; 101(3):557-569.","DOI":"10.1007\/s00277-021-04734-2"},{"key":"78798","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Scott BL, Kishtagari A. Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS). Cancer Res. 2024; 84(Suppl 7):CT060.","DOI":"10.1158\/1538-7445.AM2024-CT060"},{"key":"78799","doi-asserted-by":"crossref","unstructured":"Chung HC, Lee K-W, Gainor J. ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer. Ann Oncol. 2021; 32(Suppl 3):S215-S216.","DOI":"10.1016\/j.annonc.2021.05.055"},{"key":"78800","unstructured":"ClinicalTrials.gov. Evorpacept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (ASPEN-03). ClinicalTrials.gov Identifier: NCT04675294. 2024."},{"key":"78801","unstructured":"ClinicalTrials.gov. Evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (ASPEN-04). ClinicalTrials.gov Identifier: NCT04675333. 2024."},{"key":"78802","unstructured":"ClinicalTrials.gov. A study of evorpacept (ALX148) in patients with advanced HER2+ gastric cancer (ASPEN-06). ClinicalTrials. gov Identifier: NCT05002127. 2024."},{"key":"78803","unstructured":"ClinicalTrials.gov. A study of evorpacept (ALX148) with enfortumab vedotin for subjects with urothelial carcinoma (ASPEN-07). ClinicalTrials.gov Identifier: NCT05524545. 2024."},{"key":"78804","doi-asserted-by":"crossref","unstructured":"Piro LD, White CA, Grillo-L\u00f3pez AJ. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol. 1999; 10(6):655-661.","DOI":"10.1023\/A:1008389119525"},{"key":"78805","doi-asserted-by":"crossref","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16(8):2825-2833.","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"78806","doi-asserted-by":"crossref","unstructured":"Leonard JP, Trneny M, Izutsu K. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019; 37(14):1188-1199.","DOI":"10.1200\/JCO.19.00010"},{"key":"78807","doi-asserted-by":"crossref","unstructured":"Locke FL, Ghobadi A, Jacobson CA. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019; 20(1):31-42.","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"78808","doi-asserted-by":"crossref","unstructured":"Abramson JS, Solomon SR, Arnason J. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023; 141(14):1675-1684.","DOI":"10.1182\/blood.2022018730"},{"key":"78809","doi-asserted-by":"crossref","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022; 387(24):2220-2231.","DOI":"10.1056\/NEJMoa2206913"},{"key":"78810","doi-asserted-by":"crossref","unstructured":"Thieblemont C, Phillips T, Ghesquieres H. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023; 41(12):2238-2247.","DOI":"10.1200\/JCO.22.01725"},{"key":"78811","doi-asserted-by":"crossref","unstructured":"Sehn LH, Herrera AF, Flowers CR. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020; 38(2):155-165.","DOI":"10.1200\/JCO.19.00172"},{"key":"78812","doi-asserted-by":"crossref","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020; 21(7):978-988.","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"78813","doi-asserted-by":"crossref","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, singlearm, phase 2 trial. Lancet Oncol. 2021; 22(6):790-800.","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"78814","doi-asserted-by":"crossref","unstructured":"Crump M, Neelapu SS, Farooq U. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808.","DOI":"10.1182\/blood-2017-03-769620"},{"key":"78815","doi-asserted-by":"crossref","unstructured":"Thuresson P-O, Vander Velde N, Gupta P, Talbot J. A systematic review of the clinical efficacy of treatments in relapsed or refractory diffuse large B-cell lymphoma. Adv Ther. 2020; 37(12):4877-4893.","DOI":"10.1007\/s12325-020-01507-7"},{"key":"78816","doi-asserted-by":"crossref","unstructured":"Trabolsi A, Arumov A, Schatz JH. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J. 2024; 14(1):27.","DOI":"10.1038\/s41408-024-00997-w"},{"key":"78817","unstructured":"ClinicalTrials.gov. ALX148 rituximab and lenalidomide for the treatment of indolent and aggressive B-cell non-Hodgkin lymphoma. ClinicalTrials.gov Identifier: NCT05025800. 2024."},{"key":"78818","doi-asserted-by":"crossref","unstructured":"Strati P, Feng L, Chihara D. A phase I investigator-initiated trial of evorpacept (ALX148), lenalidomide and rituximab for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Cancer Res. 2024; 84(Suppl 7):CT037.","DOI":"10.1158\/1538-7445.AM2024-CT037"},{"key":"78819","doi-asserted-by":"crossref","unstructured":"Nikkarinen A, Lokhande L, Amini RM. Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma. Blood Adv. 2023; 7(18):5304-5313.","DOI":"10.1182\/bloodadvances.2023010052"},{"key":"78820","doi-asserted-by":"crossref","unstructured":"Rodrigues JM, Nikkarinen A, Hollander P. Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. Br J Haematol. 2021; 193(3):520-531.","DOI":"10.1111\/bjh.17366"},{"key":"78821","doi-asserted-by":"crossref","unstructured":"Le Bris Y, Normand A, Bouard L. Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis. EJHaem. 2022; 3(4):1165-1171.","DOI":"10.1002\/jha2.549"},{"key":"78822","doi-asserted-by":"crossref","unstructured":"Tan KL, Scott DW, Hong F. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood. 2012; 120(16):3280-3287.","DOI":"10.1182\/blood-2012-04-421057"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12018\/78277","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12018\/78738","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12018\/78277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:34Z","timestamp":1794046114000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286208","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}